Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Receives Average Rating of “Reduce” from Analysts

Shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC) have earned an average recommendation of “Reduce” from the twelve brokerages that are covering the company, Marketbeat Ratings reports. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and one has assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $8.20.

FULC has been the topic of several research reports. Stifel Nicolaus lowered Fulcrum Therapeutics from a “buy” rating to a “hold” rating and set a $3.00 price objective on the stock. in a research report on Tuesday, June 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Fulcrum Therapeutics in a research report on Tuesday, April 21st. Wall Street Zen upgraded Fulcrum Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, May 2nd. Jefferies Financial Group set a $4.00 target price on Fulcrum Therapeutics in a report on Tuesday, June 2nd. Finally, Citigroup lowered Fulcrum Therapeutics from an “underperform” rating to an “underweight” rating in a research report on Tuesday, June 2nd.

Fulcrum Therapeutics Price Performance

Fulcrum Therapeutics stock opened at $3.50 on Monday. The firm has a fifty day moving average of $4.93 and a 200-day moving average of $7.68. Fulcrum Therapeutics has a 52-week low of $2.83 and a 52-week high of $15.74. The firm has a market capitalization of $233.20 million, a P/E ratio of -3.04 and a beta of 3.01.

Fulcrum Therapeutics (NASDAQ:FULC) last posted its earnings results on Monday, April 27th. The company reported ($0.25) earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.06. On average, research analysts expect that Fulcrum Therapeutics will post -0.67 EPS for the current fiscal year.

Insider Activity

In other news, Director Alan Ezekowitz sold 18,000 shares of Fulcrum Therapeutics stock in a transaction that occurred on Friday, June 26th. The shares were sold at an average price of $3.65, for a total transaction of $65,700.00. Following the sale, the director owned 10,927 shares in the company, valued at $39,883.55. This trade represents a 62.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. 7.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Fulcrum Therapeutics

A number of large investors have recently added to or reduced their stakes in FULC. Braidwell LP acquired a new position in Fulcrum Therapeutics in the 3rd quarter worth $2,019,000. Boothbay Fund Management LLC grew its stake in shares of Fulcrum Therapeutics by 104.2% during the third quarter. Boothbay Fund Management LLC now owns 678,414 shares of the company’s stock valued at $6,241,000 after acquiring an additional 346,136 shares in the last quarter. Aberdeen Group plc increased its position in shares of Fulcrum Therapeutics by 809.0% during the fourth quarter. Aberdeen Group plc now owns 1,254,027 shares of the company’s stock worth $14,183,000 after acquiring an additional 1,116,066 shares during the last quarter. Catalio Capital Management LP purchased a new stake in shares of Fulcrum Therapeutics during the fourth quarter worth about $2,277,000. Finally, Nicholas Investment Partners LP acquired a new position in shares of Fulcrum Therapeutics in the fourth quarter worth about $2,069,000. 89.83% of the stock is owned by institutional investors and hedge funds.

Fulcrum Therapeutics Company Profile

Fulcrum Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing precision medicines that modulate gene expression through epigenetic control. Leveraging a proprietary target discovery platform, Fulcrum seeks to identify small‐molecule therapeutics that restore normal gene function in diseases caused by genetic dysregulation. The company’s core research efforts center on transcriptional regulators and chromatin-modifying proteins, aiming to address underlying disease mechanisms rather than downstream symptoms.

Fulcrum’s most advanced programs include FTX-6058, an oral therapeutic candidate designed to elevate fetal hemoglobin levels in patients with sickle cell disease and beta-thalassemia, and a preclinical program targeting facioscapulohumeral muscular dystrophy (FSHD) by inhibiting a key epigenetic driver of aberrant gene expression.